Verastem (VSTM) Total Liabilities (2011 - 2026)
Verastem's quarterly Total Liabilities came in at $146.0 million in Q1 2026, down 11.03% year-on-year from $164.1 million in Q1 2025, and down 22.83% quarter-over-quarter from $189.2 million in Q4 2025.
Verastem has reported Total Liabilities for 16 years, with the latest figure at $146.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities fell 11.03% year-over-year to $146.0 million; the trailing twelve-month figure through Mar 2026 stood at $146.0 million (down 11.03% YoY), and the FY2025 full-year result was $189.2 million, up 45.09% from the prior year.
- Total Liabilities for Q1 2026 stood at $146.0 million, down from $189.2 million in the prior quarter.
- The five-year high for Total Liabilities was $192.4 million in Q3 2025, with the low at $43.4 million in Q1 2022.
- Average Total Liabilities over 5 years is $99.1 million, with a median of $71.8 million recorded in 2023.
- Year-over-year, Total Liabilities soared 197.26% in 2022 and dropped 11.03% in 2026.
- Tracing VSTM's Total Liabilities over 5 years: stood at $47.7 million in 2022, then jumped by 49.36% to $71.2 million in 2023, then jumped by 83.23% to $130.4 million in 2024, then soared by 45.09% to $189.2 million in 2025, then fell by 22.83% to $146.0 million in 2026.
- The last three Total Liabilities figures came in at $146.0 million (Q1 2026), $189.2 million (Q4 2025), and $192.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | 146.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.03 Mn |
| Dec 31, 2025 | 189.25 Mn |
| Sep 30, 2025 | 192.38 Mn |
| Jun 30, 2025 | 160.21 Mn |
| Mar 31, 2025 | 164.13 Mn |
| Dec 31, 2024 | 130.43 Mn |
| Sep 30, 2024 | 94.16 Mn |
| Jun 30, 2024 | 65.74 Mn |
| Mar 31, 2024 | 77.32 Mn |
| Dec 31, 2023 | 71.19 Mn |
| Sep 30, 2023 | 71.81 Mn |
| Jun 30, 2023 | 69.01 Mn |
| Mar 31, 2023 | 66.69 Mn |
| Dec 31, 2022 | 47.66 Mn |
| Sep 30, 2022 | 48.22 Mn |
| Jun 30, 2022 | 46.52 Mn |
| Mar 31, 2022 | 43.38 Mn |
| Dec 31, 2021 | 21.10 Mn |
| Sep 30, 2021 | 16.22 Mn |
| Jun 30, 2021 | 35.69 Mn |
| Mar 31, 2021 | 34.29 Mn |
| Dec 31, 2020 | 39.08 Mn |
| Sep 30, 2020 | 88.00 Mn |
| Jun 30, 2020 | 84.16 Mn |
| Mar 31, 2020 | 85.17 Mn |
| Dec 31, 2019 | 137.87 Mn |
| Sep 30, 2019 | 171.08 Mn |
| Jun 30, 2019 | 169.23 Mn |
| Mar 31, 2019 | 154.91 Mn |
| Dec 31, 2018 | 152.94 Mn |
| Sep 30, 2018 | 75.54 Mn |
| Jun 30, 2018 | 46.05 Mn |
| Mar 31, 2018 | 29.86 Mn |
| Dec 31, 2017 | 32.11 Mn |
| Sep 30, 2017 | 22.15 Mn |
| Jun 30, 2017 | 13.61 Mn |
| Mar 31, 2017 | 15.78 Mn |
| Dec 31, 2016 | 11.33 Mn |
| Sep 30, 2016 | 6.61 Mn |
| Jun 30, 2016 | 6.36 Mn |
| Mar 31, 2016 | 6.60 Mn |
| Dec 31, 2015 | 10.63 Mn |
| Sep 30, 2015 | 11.42 Mn |
| Jun 30, 2015 | 10.44 Mn |
| Mar 31, 2015 | 10.10 Mn |
| Dec 31, 2014 | 9.88 Mn |
| Sep 30, 2014 | 9.07 Mn |
| Jun 30, 2014 | 8.16 Mn |
| Mar 31, 2014 | 6.40 Mn |
| Dec 31, 2013 | 7.82 Mn |
| Sep 30, 2013 | 5.72 Mn |
| Jun 30, 2013 | 5.27 Mn |
| Mar 31, 2013 | 3.41 Mn |
| Dec 31, 2012 | 2.46 Mn |
| Sep 30, 2012 | 3.22 Mn |
| Jun 30, 2012 | 3.30 Mn |
| Mar 31, 2012 | 3.03 Mn |
| Dec 31, 2011 | 71.80 Mn |